Patrick G. Kehoe

Best Publications

• Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

  Denise Harold;Richard Abraham;Paul Hollingworth;Rebecca Sims

  3441
  Citations

• Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.

  Paul Hollingworth;Denise Harold;Rebecca Sims;Amy Gerrish

  2310
  Citations

• Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.

  Lesley Jones;Peter A. Holmans;Marian L. Hamshere;Denise Harold

  842
  Citations

• Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations

  Lucy Webster;Derek Groskreutz;Anna Grinbergs-Saull Grinbergs-Saull;Rob Howard

  598
  Citations

• Abeta-degrading enzymes in Alzheimer's disease.

  James Scott Miners;Shabnam Baig;Jennifer Palmer;Laura E Palmer

  540
  Citations

• Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease

  C Cruchaga;CM Karch;SC Jin;BA Benitez

  530
  Citations

• Drug repositioning for Alzheimer's disease

  Anne Corbett;James Pickett;Alistair Burns;Jonathan Corcoran

  351
  Citations

• Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease

  James Scott Miners;Neil Barua;Patrick Gavin Kehoe;Steven Gill

  319
  Citations

• Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment

  Olivia A. Skrobot;Johannes Attems;Margaret Esiri;Tibor Hortobágyi;Tibor Hortobágyi

  294
  Citations

• Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.

  Silke Krol;Richard Macrez;Fabian Docagne;Gilles Defer

  231
  Citations

• Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease?

  Patrick Gavin Kehoe;Gordon K Wilcock

  225
  Citations

• Cognitive impact of COVID-19: looking beyond the short term.

  Scott Miners;Patrick G. Kehoe;Seth Love

  203
  Citations

• Convergent genetic and expression data implicate immunity in Alzheimer's disease

  Lesley Jones;Jean-Charles Lambert;Jean-Charles Lambert;Jean-Charles Lambert;Li-San Wang;Seung-Hoan Choi

  195
  Citations

• Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.

  James Scott Miners;Zoë Van Helmond;Katy Chalmers;Gordon Wilcock

  193
  Citations

• Angiotensins in Alzheimer's disease – friend or foe?

  Patrick G. Kehoe;Scott Miners;Seth Love

  190
  Citations

• Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes

  Scott Miners;Emma Ashby;Shabnam Baig;Rachel Harrison

  189
  Citations

• Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy.

  J S Miners;EL Ashby;Z van Helmond;Katy A Chalmers

  184
  Citations

• ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease

  Charles E. Evans;James S. Miners;Giulia Piva;Christine L. Willis

  141
  Citations

• Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis

  Ruth Peters;Ruth Peters;Sevil Yasar;Craig S. Anderson;Craig S. Anderson;Craig S. Anderson;Shea Andrews

  140
  Citations

• VEGF-A165b Is an Endogenous Neuroprotective Splice Isoform of Vascular Endothelial Growth Factor A in Vivo and in Vitro

  Nick Beazley-Long;Jing Hua;Thomas Jehle;Richard P. Hulse

  131
  Citations